Literature DB >> 16136144

Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

Gerald Willimsky1, Thomas Blankenstein.   

Abstract

The recognition and elimination of tumours by T cells, a process termed cancer immunosurveillance, is effective against certain virus-associated cancers. Spontaneous tumours often induce a specific immune response and are therefore also immunogenic. However, it is not clear whether they can be controlled by T cells. The immunosurveillance hypothesis postulates that tumours, if they eventually grow, escaped T-cell recognition by losing immunogenicity. Here we show, by generating a mouse model of sporadic cancer based on rare spontaneous activation of a dormant oncogene, that immunogenic tumours do not escape their recognition but induce tolerance. In this model, tumours derive from single cells and express a tumour-specific transplantation rejection antigen. Whereas vaccinated mice remain tumour-free throughout their lifetime, naive mice always develop a progressively growing tumour. We also show that despite specific recognition by T cells, the tumours do not lose their intrinsic immunogenicity and are rejected after transplantation in T-cell-competent recipients. Furthermore, in the primary host tumour-induced tolerance is associated with the expansion of non-functional T cells. Together, our data argue against immunosurveillance of spontaneous cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16136144     DOI: 10.1038/nature03954

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  148 in total

1.  Depot formation of doxycycline impairs Tet-regulated gene expression in vivo.

Authors:  Kathleen Anders; Christian Buschow; Jehad Charo; Thomas Blankenstein
Journal:  Transgenic Res       Date:  2011-12-14       Impact factor: 2.788

2.  Role of CXCR3 ligands in IL-7/IL-7R alpha-Fc-mediated antitumor activity in lung cancer.

Authors:  Asa Andersson; Minu K Srivastava; Marni Harris-White; Min Huang; Li Zhu; David Elashoff; Robert M Strieter; Steven M Dubinett; Sherven Sharma
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

Review 3.  Myeloid suppressor cells and immune modulation in lung cancer.

Authors:  Minu K Srivastava; Åsa Andersson; Li Zhu; Marni Harris-White; Jay M Lee; Steven Dubinett; Sherven Sharma
Journal:  Immunotherapy       Date:  2012-03       Impact factor: 4.196

4.  Early tumor dissemination, but late metastasis: insights into tumor dormancy.

Authors:  Martin Röcken
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

5.  Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer.

Authors:  Daniel Delitto; Chelsey Perez; Song Han; David H Gonzalo; Kien Pham; Andrea E Knowlton; Christina L Graves; Kevin E Behrns; Lyle L Moldawer; Ryan M Thomas; Chen Liu; Thomas J George; Jose G Trevino; Shannon M Wallet; Steven J Hughes
Journal:  Cancer Immunol Immunother       Date:  2015-09-30       Impact factor: 6.968

Review 6.  Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.

Authors:  Arnab Ghosh; Amanda M Holland; Marcel R M van den Brink
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

7.  Normal ageing is associated with an increase in Th2 cells, MCP-1 (CCL1) and RANTES (CCL5), with differences in sCD40L and PDGF-AA between sexes.

Authors:  A S Mansfield; W K Nevala; R S Dronca; A A Leontovich; L Shuster; S N Markovic
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

Review 8.  Tolerance and exhaustion: defining mechanisms of T cell dysfunction.

Authors:  Andrea Schietinger; Philip D Greenberg
Journal:  Trends Immunol       Date:  2013-11-06       Impact factor: 16.687

9.  Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity.

Authors:  Ingunn M Stromnes; J Scott Brockenbrough; Kamel Izeradjene; Markus A Carlson; Carlos Cuevas; Randi M Simmons; Philip D Greenberg; Sunil R Hingorani
Journal:  Gut       Date:  2014-02-20       Impact factor: 23.059

10.  Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.

Authors:  Andrea Schietinger; Mary Philip; Varintra E Krisnawan; Edison Y Chiu; Jeffrey J Delrow; Ryan S Basom; Peter Lauer; Dirk G Brockstedt; Sue E Knoblaugh; Günter J Hämmerling; Todd D Schell; Natalio Garbi; Philip D Greenberg
Journal:  Immunity       Date:  2016-08-09       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.